Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.1
4.9
Journals
IJMS
Special Issues
Application of Nanomaterials in Cancer Diagnostic and Therapy
ijms-logo
Submit to IJMS Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Application of Nanomaterials in Cancer Diagnostic and Therapy

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Nanoscience".

Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 5603

Special Issue Editor

Dr. János Borbély

E-Mail Website
Guest Editor
1. Doctoral School of Clinical Medicine, University of Debrecen, Debrecen, Hungary
2. BBS Dominus LLC, Debrecen, Hungary
Interests: nanomedicine: nanocomposites for cancer diagnosis and treatment, in vitro, in vivo; pharmaceutics

Special Issue Information

Dear Colleagues, 

Over the past few decades, great efforts have been devoted to cancer research. In most cases, it is difficult to detect cancer at an early stage. Traditional chemotherapy or radiation therapy is severely hampered by low efficacy and significant side effects. In recent years, advances in nanotechnology have propelled the development of nanomedicine in cancer diagnosis and treatment. To date, various nanomaterials have been designed for nanomedicine; based on these nanomaterials, various nanoprobes and therapeutic nanoplatforms have been developed. Compared with traditional molecular drugs, nanomedicines have a longer circulation time, higher diagnostic sensitivity, and stronger therapeutic effect. Nanomedicine is expected to be a potential tool for cancer diagnosis and treatment. To overcome tumor metastasis and drug resistance, there is a great need to develop nanomedicines with multiple therapeutic modalities, most of which are also composed of polymers or metal-containing nanomaterials. Therefore, the development of functional nanoplatforms with extended circulation times and strong tumor-targeting capabilities is highly desirable. The research topics of this Special Issue are designed to cover promising, recent, and novel research trends in nanomaterials for cancer diagnosis and therapy.

Dr. János Borbély
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

18 pages, 6315 KiB  
Article
Engineered Mesoporous Silica-Based Core-Shell Nanoarchitectures for Synergistic Chemo-Photodynamic Therapies
by Yue-Mei Gao, Shih-Han Chiu, Prabhakar Busa, Chen-Lun Liu, Ranjith Kumar Kankala and Chia-Hung Lee
Int. J. Mol. Sci. 2022, 23(19), 11604; https://doi.org/10.3390/ijms231911604 - 1 Oct 2022
Cited by 3 | Viewed by 2708
Abstract
Combinatorial therapies have garnered enormous interest from researchers in efficiently devastating malignant tumors through synergistic effects. To explore the combinatorial approach, multiple therapeutic agents are typically loaded in the delivery vehicles, controlling their release profiles and executing subsequent therapeutic purposes. Herein, we report [...] Read more.
Combinatorial therapies have garnered enormous interest from researchers in efficiently devastating malignant tumors through synergistic effects. To explore the combinatorial approach, multiple therapeutic agents are typically loaded in the delivery vehicles, controlling their release profiles and executing subsequent therapeutic purposes. Herein, we report the fabrication of core (silica)-shell (mesoporous silica nanoparticles, MSNs) architectures to deliver methylene blue (MB) and cupric doxorubicin (Dox) as model drugs for synergistic photodynamic therapy (PDT), chemotherapy, and chemodynamic therapy (CDT). MB, as the photosensitizer, is initially loaded and stabilized in the silica core for efficient singlet oxygen generation under light irradiation towards PDT. The most outside shell with imidazole silane-modified MSNs is immobilized with a chemotherapeutic agent of Dox molecules through the metal (Copper, Cu)-ligand coordination interactions, achieving the pH-sensitive release and triggering the production of intracellular hydrogen peroxide and subsequent Fenton-like reaction-assisted Cu-catalyzed free radicals for CDT. Further, the designed architectures are systematically characterized using various physicochemical characterization techniques and demonstrate the potent anti-cancer efficacy against skin melanoma. Together our results demonstrated that the MSNs-based core-shell nanoarchitectures have great potential as an effective strategy in synergistically ablating cancer through chemo-, chemodynamic, and photodynamic therapies. Full article
(This article belongs to the Special Issue Application of Nanomaterials in Cancer Diagnostic and Therapy)
►▼ Show Figures

Figure 1

23 pages, 4878 KiB  
Article
Comparative Analysis of the Cytotoxic Effect of a Complex of Selenium Nanoparticles Doped with Sorafenib, “Naked” Selenium Nanoparticles, and Sorafenib on Human Hepatocyte Carcinoma HepG2 Cells
by Elena G. Varlamova, Mikhail V. Goltyaev, Aleksander V. Simakin, Sergey V. Gudkov and Egor A. Turovsky
Int. J. Mol. Sci. 2022, 23(12), 6641; https://doi.org/10.3390/ijms23126641 - 14 Jun 2022
Cited by 13 | Viewed by 2420
Abstract
Despite the use of sorafenib as one of the most effective drugs for the treatment of liver cancer, its significant limitations remain—poor solubility, the need to use high doses with the ensuing complications on healthy tissues and organs, and the formation of cell [...] Read more.
Despite the use of sorafenib as one of the most effective drugs for the treatment of liver cancer, its significant limitations remain—poor solubility, the need to use high doses with the ensuing complications on healthy tissues and organs, and the formation of cell resistance to the drug. At the same time, there is more and more convincing evidence of the anticancer effect of selenium-containing compounds and nanoparticles. The aim of this work was to develop a selenium–sorafenib nanocomplex and study the molecular mechanisms of its anticancer effect on human hepatocyte carcinoma cells, where nanoselenium is not only a sorafenib transporter, but also an active compound. We have created a selenium–sorafenib nanocomplex based on selenium nanoparticles with size 100 nm. Using vitality tests, fluorescence microscopy, and PCR analysis, it was possible to show that selenium nanoparticles, both by themselves and doped with sorafenib, have a pronounced pro-apoptotic effect on HepG2 cells with an efficiency many times greater than that of sorafenib (So). “Naked” selenium nanoparticles (SeNPs) and the selenium–sorafenib nanocomplex (SeSo), already after 24 h of exposure, lead to the induction of the early stages of apoptosis with the transition to the later stages with an increase in the incubation time up to 48 h. At the same time, sorafenib, at the studied concentrations, began to exert a proapoptotic effect only after 48 h. Under the action of SeNPs and SeSo, both classical pathways of apoptosis induction and ER-stress-dependent pathways involving Ca2+ ions are activated. Thus, sorafenib did not cause the generation of Ca2+ signals by HepG2 cells, while SeNPs and SeSo led to the activation of the Ca2+ signaling system of cells. At the same time, the selenium–sorafenib nanocomplex turned out to be more effective in activating the Ca2+ signaling system of cells, inducing apoptosis and ER stress by an average of 20–25% compared to “naked” selenium nanoparticles. Our data on the mechanisms of action and the created nanocomplex are promising as a platform for the creation of highly selective and effective drugs with targeted delivery to tumors. Full article
(This article belongs to the Special Issue Application of Nanomaterials in Cancer Diagnostic and Therapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop